Millennium Management’s Alterity Therapeutics ATHE Stock Holding History

Millennium Management’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,684	Closed	-$34K	–	6344
2022 Q4	$34K	Buy	9,684 +8,363	+633%	+$32K	﹤0.01%	5898
2022 Q3	$6K	Buy	+1,321	New	+$7.74K	﹤0.01%	6767
2021 Q3	–	Sell	-3,694	Closed	-$48K	–	6762
2021 Q2	$48K	Buy	+3,694	New	+$50.1K	﹤0.01%	6373
2014 Q1	–	Sell	-658	Closed	-$277K	–	3435
2013 Q4	$277K	Buy	+658	New	+$197K	﹤0.01%	3089

Other funds holding ATHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

TLCM

Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return

PCA

Providence Capital Advisors Charlotte, North Carolina $613M AUM 17.83% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SWM

Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Millennium Management's ATHE Position: Q1 2023 in Review

Millennium Management sold out of Alterity Therapeutics (ATHE) in Q1 2023, closing a stake of 9,684 shares — an estimated $34K sold.

Millennium Management first reported a position in ATHE in Q4 2013 and held it in 4 quarters. The position peaked at $277K in Q4 2013. 7 funds tracked by Wall St. Rank hold ATHE as of Q1 2023.

Millennium Management reported no remaining Alterity Therapeutics position as of Q1 2023 after selling out during the quarter.
Millennium Management sold 9,684 Alterity Therapeutics shares in Q1 2023, an estimated $34K.
Millennium Management first reported a position in Alterity Therapeutics in Q4 2013 and held it in 4 quarters.
Millennium Management's Alterity Therapeutics position peaked at $277K in Q4 2013.
7 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.